No Data
No Data
Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SH): has not yet launched business in the field of cell therapy
Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SH) stated on the investor interaction platform that the company is currently focused on the research and development, production, and sales of in vitro diagnostic reagents, supporting testing instruments, and other in vitro diagnostic products. It focuses on disease prevention and control (CDC) and clinical maternal and child testing, and has not yet engaged in the field of cell therapy business.
Jiangsu Bioperfectus Technologies Co.,Ltd. (688399.SH): has repurchased 2.07% of the shares.
On September 2, Gleonhui announced that as of September 2, 2024, Jiangsu Bioperfectus Technologies Co.,Ltd. (688399.SH) has repurchased a total of 1.21066 million shares through centralized bidding trading, accounting for 2.07% of the total share capital. The highest purchase price is 79.70 yuan/share, the lowest purchase price is 69.70 yuan/share, and the total amount paid is 92.0759 million yuan (excluding stamp duty, trading commission, and other transaction fees).
Jiangsu Shuoshi Biotechnology Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Jiangsu Shuoshi Biotechnology Co., Ltd.
Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SH) released its performance for the first half of the year, with a net income of 29.2405 million yuan, turning losses into profits year-on-year.
Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SH) released its semi-annual report for 2024, during which the company achieved revenue of 1...
Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SH): The monkeypox detection products are exported to some African countries.
On August 21, Bioperfectus Technologies (688399.SH) stated on the investor interactive platform that the company's monkey pox detection products are exported to some African countries. Currently, the revenue from overseas market business accounts for a small proportion of the company's overall business income. The company will closely monitor the overseas market situation.
No Data
No Data